Page Title
Drug Development Pipeline
Adrulipase (formerly MS1819-SD)
Status
Phase TwoTherapeutic Approach
Nutritional-GI
Adrulipase (formerly MS1819-SD) is a non-porcine, meaning not pig-derived, enzyme for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from the yeast Yarrowia lipolytica. This drug does not contain any animal products.
Status
In 2018, a Phase 2a study of MS1819-SD was conducted in people with chronic pancreatitis. The study showed that adrulipase was safe and may potentially improve fat absorption.
A Phase 2 study in people with CF was completed. This study compared adrulipase to currently available porcine-derived enzymes.
Sponsor
This program is sponsored by First Wave Biopharma (formerly AzurRx Biopharma). It is being conducted within the Therapeutics Development Network (TDN).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More